Investment Bridge, one of Japan's leading IR services companies, has released a “Bridge Report” on euglena Co., Ltd. (TOKYO Mothers: 2931) reviewing first half fiscal year September 2013 earnings results and full year fiscal year September 2013 earnings estimates. Report Highlights * euglena Co., Ltd. is the world's first biotechnology company to succeed in outdoor mass culture of edible Euglena microalgae. * Sales of food products in the direct sales business exceeded food sales of the health care business, which is trending favorably, due to fortification of the marketing structure and increases in brand awareness of the main product of “euglena farm Vegetable Juice (Japanese: “Midorijiru”).” * Steady progress is being made in the achievement of three initial objectives of the research and development for bio-jet fuels. * Key points of euglena's strategy include the speed of expansion of its direct sales business over the near term and commercialization of the jet fuel business by 2018 over the medium term. euglena is the world's first biotechnology company to succeed in outdoor mass culture of edible euglena microalgae. Euglena has superior characteristics that can be leveraged in foods, cosmetics, chemical products, feeds, fuels and other products. Amongst the strengths of euglena Co., Ltd. are the high profitability and stable cash flow of its health care business, and strong research and development function, which collaborates with famous corporations and universities. About Bridge Report: Bridge Report is produced by Investment Bridge Co., Ltd. and provides accurate and objective information about the earnings, business strategies, and other information of publicly traded Japanese companies. Contact: Investment Bridge Co., Ltd. mailto:firstname.lastname@example.org Contributed via: Bloomberg Publisher WEB Service
Bridge Report on euglena Co., Ltd. Issued: 1H FY9/13 Results and FY9/13 Estimates
Press spacebar to pause and continue. Press esc to stop.